Sinjard-L 10/5

Presentation: Tablets containing 10 mg of empagliflozin and 5 mg of linagliptin.

Indications: Sinjard-L 10/5 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.  

Dosage and Administration: The recommended dose is one tablet (10 mg empagliflozin/5 mg linagliptin) once daily. It can be taken orally once daily with or without food. If used in combination with a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. The dosage should be individualized based on the patient's current regimen, effectiveness, and tolerability, not exceeding the maximum recommended daily dose of 10 mg empagliflozin and 5 mg linagliptin.

Side Effects: Common side effects associated with empagliflozin may include urinary tract infections and increased urination. Common side effects associated with linagliptin may include nasopharyngitis (common cold) and headache. When used in combination, other possible side effects include hypoglycemia (low blood sugar), especially when used with insulin or sulfonylureas. Less common but potentially serious side effects can occur. Report any persistent or troublesome side effects to your doctor.

Precautions:

• Inform your doctor about any pre-existing medical conditions, especially kidney disease, liver disease, heart failure, pancreatitis, a history of urinary tract infections, or allergic reactions to empagliflozin or linagliptin.
• Sinjard-L 10/5 should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
• Assess renal function before initiating Sinjard-L 10/5 and periodically thereafter.
• Be aware of the risk of hypoglycemia when Sinjard-L 10/5 is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin.
• There have been reports of ketoacidosis in patients with type 1 and type 2 diabetes receiving SGLT2 inhibitors (like empagliflozin).
• Discontinue Sinjard-L 10/5 if pancreatitis is suspected.
• Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding, as Sinjard-L 10/5 may not be suitable in these situations.
• Be aware of potential drug interactions and inform your doctor about all other medications you are taking, including over-the-counter drugs and herbal supplements.  

Storage:   Store below 30°C, protected from light and moisture. Keep out of the reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.